Literature DB >> 10384685

Barriers to compliance with screening guidelines for diabetic retinopathy.

D B Mukamel1, G H Bresnick, Q Wang, C F Dickey.   

Abstract

OBJECTIVE: To identify barriers to compliance with guidelines for diabetic retinopathy screening.
METHODS: The population studied included 4410 adults, aged 31 to 64, enrolled in an Independent Practice Association (IPA) plan in Upstate New York, who were diagnosed with diabetes, and their Primary Care Physicians (408 PCPs). Claims data were used to calculate variables characterizing patients and their PCPs. Logistic regression models were estimated to identify factors associated with higher probability of screening.
RESULTS: 34% of patients were screened in 1993. The probability of screening was significantly higher for older patients, for women, for patients who visit their PCPs more often and for those living in areas of higher average education and lower percentage of blacks. However, only 16% of diabetic patients received an annual screen in two consecutive years (1992 and 1993). The probability of consecutive annual screening was significantly associated only with gender and patient expenditures per month.
CONCLUSION: The very low rate of diabetic retinopathy screening has implications for quality of life of patients with diabetes, long term costs of caring for them and social costs due to lost productivity. Interventions to increase screening rates are needed and should target both patients and their Primary Care Physicians.

Entities:  

Mesh:

Year:  1999        PMID: 10384685     DOI: 10.1076/opep.6.1.61.1563

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  24 in total

1.  EyePACS: an adaptable telemedicine system for diabetic retinopathy screening.

Authors:  Jorge Cuadros; George Bresnick
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

Review 2.  Smartphones, tele-ophthalmology, and VISION 2020.

Authors:  Mehrdad Mohammadpour; Zahra Heidari; Masoud Mirghorbani; Hassan Hashemi
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

3.  Report on the creation of a diabetes register and retinopathy screening outcomes in the Mid-West of Ireland.

Authors:  M James; C Goodchild; S Bashir; M Mannix
Journal:  Ir J Med Sci       Date:  2015-01-17       Impact factor: 1.568

4.  Diabetic Retinopathy: Focus on Minority Populations.

Authors:  Arpine Barsegian; Boleslav Kotlyar; Justin Lee; Moro O Salifu; Samy I McFarlane
Journal:  Int J Clin Endocrinol Metab       Date:  2017-11-11

Review 5.  Treatment of diabetic retinopathy: Recent advances and unresolved challenges.

Authors:  Michael W Stewart
Journal:  World J Diabetes       Date:  2016-08-25

6.  Automated detection of proliferative retinopathy in clinical practice.

Authors:  Audrey Karperien; Herbert F Jelinek; Jorge J G Leandro; João V B Soares; Roberto M Cesar; Alan Luckie
Journal:  Clin Ophthalmol       Date:  2008-03

7.  Retinopathy of prematurity management using single-image vs multiple-image telemedicine examinations.

Authors:  Alexandra Lajoie; Susan Koreen; Lu Wang; Steven A Kane; Thomas C Lee; David J Weissgold; Audina M Berrocal; Yunling E Du; Osode Coki; John T Flynn; Justin Starren; Michael F Chiang
Journal:  Am J Ophthalmol       Date:  2008-06-10       Impact factor: 5.258

8.  Primary care physicians' knowledge of the ophthalmic effects of diabetes.

Authors:  Michael N Wiggins; Reid D Landes; Swetangi D Bhaleeya; Sami H Uwaydat
Journal:  Can J Ophthalmol       Date:  2013-08       Impact factor: 1.882

9.  Vision is precious: a successful behavioral intervention to increase the rate of screening for diabetic retinopathy for inner-city adults.

Authors:  Hollie L Jones; Elizabeth A Walker; Clyde B Schechter; Emelinda Blanco
Journal:  Diabetes Educ       Date:  2009-12-31       Impact factor: 2.140

10.  Analysis of reasons for noncompliance with laser treatment in patients of diabetic retinopathy.

Authors:  Wen Hua; Sijia Cao; Jing Cui; David Maberley; Joanne Matsubara
Journal:  Can J Ophthalmol       Date:  2013-04       Impact factor: 1.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.